慢性阻塞性肺疾病患者FENO變化的臨床意義及其與FEV1，F(xiàn)EV1%相關(guān)性研究
發(fā)布時(shí)間：2018-07-21 17:34
【摘要】：目的(1)分析慢性阻塞性肺疾病患者急性加重期(acute exacrbations of chronic obstructive pulmonary diseases,AECOPD)、穩(wěn)定期及健康對(duì)照者的呼出氣一氧化氮(fractional exhaled nitrie oxide,FENO)值;比較COPD患者急性加重期及穩(wěn)定期的FENO探討FENO在評(píng)估住院AECOPD患者氣道炎癥中的作用。(2)分析COPD患者急性加重期與穩(wěn)定期FENO值與療效的關(guān)系,探討FENO值測(cè)定對(duì)住院COPD患者急性加重期治療效果的評(píng)估意義。方法(1)以81例COPD急性加重期到穩(wěn)定期患者為研究組,78例健康者為對(duì)照組,運(yùn)用呼出氣一氧化氮測(cè)定儀器NIOXMINO測(cè)定FENO值;同時(shí)使用肺功能儀肺功能計(jì)量器(美國(guó)麥加菲肺功能測(cè)試系統(tǒng)ELITE DL)測(cè)定其第一秒用力呼氣容積(forced expiratory volume in one second,FEV1)、第一秒用力呼氣容積占預(yù)計(jì)值的百分比(forced expiratory volume in one second/predicated value,FEV1%)。(2)COPD急性加重期患者進(jìn)行綜合治療后,測(cè)定其穩(wěn)定期FENO值及FEV1、FEV1%。結(jié)果(1)COPD患者急性加重期組FENO水平高于穩(wěn)定期組;(2)COPD穩(wěn)定期組FENO水平高于對(duì)照組;(3)COPD急性加重期組FENO水平高于穩(wěn)定期組和對(duì)照組(P0.05);(4)相關(guān)關(guān)系研究發(fā)現(xiàn):COPD急性加重期組患者FENO水平與FEV1、FEV1%均無(wú)相關(guān)性(P0.05);COPD穩(wěn)定期組患者FENO水平與FEV1、FEV1%均無(wú)相關(guān)性(P0.05);急性加重期到穩(wěn)定期FENO改善值與急性加重期到穩(wěn)定期FEV1改善值之間存在正相關(guān)關(guān)系(P0.05),與急性加重期到穩(wěn)定期FEV1%改善值之間亦存在正相關(guān)關(guān)系(P0.05)。結(jié)論(1)呼出氣一氧化氮測(cè)定方法簡(jiǎn)單易行,具有無(wú)創(chuàng)、可重復(fù)且質(zhì)控嚴(yán)格的優(yōu)點(diǎn)。COPD急性加重期患者FENO值高于對(duì)照組,COPD穩(wěn)定期患者FENO值下降;提示FENO可以反應(yīng)COPD急性加重期患者氣道炎癥。(2)COPD急性加重期患者及COPD穩(wěn)定期患者其FENO值下降程度與治療后肺功能的改善存在相關(guān)性。
[Abstract]:Objective (1) to analyze the value of exhaled nitric oxide (fractional exhaled nitrie) in patients with acute exacerbation of chronic obstructive pulmonary disease (acute exacrbations of chronic obstructive pulmonary), stable stage and healthy controls. To investigate the role of FENO in evaluating airway inflammation in hospitalized AECOPD patients. (2) to analyze the relationship between FENO and efficacy in acute exacerbation and stable COPD patients. Objective: to evaluate the effect of FENO determination in acute exacerbation of COPD patients. Methods (1) Eighty-one COPD patients from acute exacerbation stage to stable stage were used as study group and 78 healthy subjects as control group. The FENO value was measured by the exhalation nitric oxide (NIOXMINO) instrument. Lung function Meter (American McGarfield Pulmonary function Measurement system ELITE DL) was used to measure the forced expiratory volume (forced expiratory volume in one second FEV1) and the percentage of forced expiratory volume in the first second (forced expiratory volume in one second/predicated) to the predicted value. Value of FEV1%). (2) after comprehensive treatment in patients with acute exacerbation of). (, The FENO value and FEV _ 1 of FEV _ 1 were measured. Results (1) the level of FENO in the acute exacerbation group was higher than that in the stable phase group, (2) the FENO level in the stable phase group was higher than that in the control group, and (3) the FENO level in the acute exacerbation group was higher than that in the stable phase group and the control group (P0.05). There was no correlation between FENO level and FEV1% (P0.05), there was no correlation between FENO level and FEV1% in COPD stable group (P0.05), and there was a positive correlation between FENO improvement value and FEV1 improvement value in acute exacerbation period to stable phase (P0.05), and there was a positive correlation between FENO level and FEV1 improvement value during acute exacerbation period to stable phase (P0.05), and there was a positive correlation between FENO level and FEV1 improvement value during acute exacerbation period to stable phase (P0.05). There was also a positive correlation between FEV 1% improvement value and stable FEV improvement value (P0.05). Conclusion (1) the determination method of exhalation nitric oxide is simple, noninvasive, repeatable and strict in quality control. The FENO value of COPD patients in acute exacerbation stage is higher than that in the control group. The results suggest that FENO can reflect airway inflammation in patients with acute exacerbation of COPD. (2) the decrease of FENO in patients with acute exacerbation of COPD and stable COPD is related to the improvement of pulmonary function after treatment.
【學(xué)位授予單位】：石河子大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2016
【分類號(hào)】：R563.9
，
本文編號(hào)：2136270
[Abstract]:Objective (1) to analyze the value of exhaled nitric oxide (fractional exhaled nitrie) in patients with acute exacerbation of chronic obstructive pulmonary disease (acute exacrbations of chronic obstructive pulmonary), stable stage and healthy controls. To investigate the role of FENO in evaluating airway inflammation in hospitalized AECOPD patients. (2) to analyze the relationship between FENO and efficacy in acute exacerbation and stable COPD patients. Objective: to evaluate the effect of FENO determination in acute exacerbation of COPD patients. Methods (1) Eighty-one COPD patients from acute exacerbation stage to stable stage were used as study group and 78 healthy subjects as control group. The FENO value was measured by the exhalation nitric oxide (NIOXMINO) instrument. Lung function Meter (American McGarfield Pulmonary function Measurement system ELITE DL) was used to measure the forced expiratory volume (forced expiratory volume in one second FEV1) and the percentage of forced expiratory volume in the first second (forced expiratory volume in one second/predicated) to the predicted value. Value of FEV1%). (2) after comprehensive treatment in patients with acute exacerbation of). (, The FENO value and FEV _ 1 of FEV _ 1 were measured. Results (1) the level of FENO in the acute exacerbation group was higher than that in the stable phase group, (2) the FENO level in the stable phase group was higher than that in the control group, and (3) the FENO level in the acute exacerbation group was higher than that in the stable phase group and the control group (P0.05). There was no correlation between FENO level and FEV1% (P0.05), there was no correlation between FENO level and FEV1% in COPD stable group (P0.05), and there was a positive correlation between FENO improvement value and FEV1 improvement value in acute exacerbation period to stable phase (P0.05), and there was a positive correlation between FENO level and FEV1 improvement value during acute exacerbation period to stable phase (P0.05), and there was a positive correlation between FENO level and FEV1 improvement value during acute exacerbation period to stable phase (P0.05). There was also a positive correlation between FEV 1% improvement value and stable FEV improvement value (P0.05). Conclusion (1) the determination method of exhalation nitric oxide is simple, noninvasive, repeatable and strict in quality control. The FENO value of COPD patients in acute exacerbation stage is higher than that in the control group. The results suggest that FENO can reflect airway inflammation in patients with acute exacerbation of COPD. (2) the decrease of FENO in patients with acute exacerbation of COPD and stable COPD is related to the improvement of pulmonary function after treatment.
【學(xué)位授予單位】：石河子大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2016
【分類號(hào)】：R563.9
，
本文編號(hào)：2136270
本文鏈接：http://sikaile.net/yixuelunwen/huxijib/2136270.html
最近更新
教材專著
